High intensity focused ultrasound in combination with chemotherapy by the regime of PFC：a clinical study for advanced gastric carcinoma

Objective： To evaluate the recent curative efficacy and security of High intensity focused ultrasound （HIFU） in combination with chemotherapy（PFC） in patients with advanced gastric carcinoma. Method： Sixty patients with measurable advanced gastric carcinoma, proved pathologically, were divided into Group A and Group B. Group A： Patients were treated by HIFU（FEP-BY01） in combination with chemotherapy（PFC, paclitaxel, cisplatin and 5-fluorouracil）. Group B： Patients were treated with the single regime of PFC. Results： All cases could be evaluated, ha group A, 5 patients achieved complete response, 17 patients achieved partial response,and a response rate was 73.3%. The stable disease（SD） and the inefficiency all were 13.3% （4/30） respectively, and msurvival time（MST） was 13.9 months. In group B, 2 patients achieved complete response, 14 patients achieved partial response, and a response rate was 53.3%. The stable disease（SD） was 23.3%（7/30）. The inefficiency all were 23.3%（7/30） respectively, and median survival time was 9.6 months. There was significant difference between two groups MST（ P 〈 0.05）. Major toxicities included bone marrow depression, nausea, vomiting and alopecia, without significant differences between two groups（ P 〉 0.05）. Conclusion： This study shows that HIFU in combination with chemotherapy（PFC） was a new efficent and secure therapy for the patients with advanced gastric carcinoma. It was observed that the MST was prolonged. Prospective trials should be warranted to determine the result.

High intensity focused ultrasound in combination with chemotherapy by the regime of PFC: a clinical study for advanced gastric carcinoma

Objective: To evaluate the recent curative efficacy and security of High intensity focused ultrasound (HIFU) in combination with chemotherapy(PFC) in patients with advanced gastric carcinoma. Method: Sixty patients with measurable advanced gastric carcinoma,proved pathologically, were divided into Group A and Group B. Group A: Patients were treated by HIFU(FEP-BY01) in combination with chemotherapy(PFC, paclitaxel, cisplatin and 5-fluorouracil). Group B: Patients were treated with the single regime of PFC. Results: All cases could be evaluated. In group A, 5 patients achieved complete response, 17 patients achieved partial response,and a response rate was 73.3%. The stable disease(SD) and the inefficiency all were 13.3%(4/30) respectively, and msurvival time(MST) was 13.9 months. In group B, 2 patients achieved complete response, 14 patients achieved partial response,and a response rate was53.3%. The stable disease(SD) was 23.3%(7/30). The inefficiency all were 23.3%(7/30) respectively, and median survival time was 9.6 months. There was significant difference between two groups' MST(P<0.05). Major toxicities included bone marrow depression, nausea, vomiting and alopecia, without significant differences between two groups(P>0.05). Conclusion: This study shows that HIFU in combination with chemotherapy(PFC) was a new efficent and secure therapy for the patients with advanced gastric carcinoma. It was observed that the MST was prolonged. Prospective trials should be warranted to determine the result.